ian day edited presentation

27
The potential of genetics to enable personalization of healthcare Professor Ian N M Day MRC Centre (CAiTE) and Bristol Genetic Epidemiology Laboratory Department of Social Medicine Oakfield House, Oakfield Grove University of Bristol Bristol Enterprise Network event „The Personalised Healthcare Revolution‟ 8th October 2009 Bristol Zoo

Upload: bath-bristol-enterprise-network

Post on 26-Jun-2015

910 views

Category:

Technology


0 download

DESCRIPTION

BEN Event: Personalised Healthcare - 8th October 2009

TRANSCRIPT

Page 1: Ian Day Edited Presentation

The potential of genetics

to enable personalization of healthcare

Professor Ian N M Day

MRC Centre (CAiTE) and

Bristol Genetic Epidemiology Laboratory

Department of Social Medicine

Oakfield House, Oakfield Grove

University of Bristol

Bristol Enterprise Network event „The Personalised Healthcare Revolution‟

8th October 2009

Bristol Zoo

Page 2: Ian Day Edited Presentation

What is in your genome?

• 3000 million A,C,G,T bases strung together into 23 long

molecules (chromosomes)

• The base sequence is your blueprint

• There are about 20,000 ‘genes’

• Each gene encodes a protein, e.g.haemoglobin

• 99% does NOT encode proteins. ?junk

• About 1% of bases are ‘polymorphic’

• You may have about 1m more ‘private’ variations

• Mutation of one base may cause a major disease

• You are 96% the same as chimp, 99.5% in protein coding

Page 3: Ian Day Edited Presentation

Where is your genome?

• There is a copy in every cell of your body

• Different genes are active in different cells

• However, you only copy half your genome

into a sperm or an egg

Page 4: Ian Day Edited Presentation

Does the hypercholesterolaemia run

in the family with the LDLR gene?

Page 5: Ian Day Edited Presentation

Melt-MADGE

Loading the gel

Glass-gel-glass sandwich

Pouring one gel Pouring 16 gels

Melt-MADGE system

Melt-MADGE tank

Page 6: Ian Day Edited Presentation

“ScanLab”(same system to run melts and endoVII assays)

>>Goal – studying unknown mutations in populations … studies in

big case collections also feasible

>>Present capacity – 10 systems – 50million base pairs scanned per week

Page 7: Ian Day Edited Presentation

Found 1 severe mutation in MC4R

in 1,100 population sample• Khalid K. Alharbi1, Emmanuel Spanakis1,

Karen Tan2, Matt J. Smith1, Mohammed A. Aldahmesh1, Sandra D. O'Dell1, Avan Aihie Sayer3, Debbie A. Lawlor4, Shah Ebrahim5, George Davey Smith4, Stephen O’Rahilly3, Sadaf Farooqi2 , Cyrus Cooper3, David I.W.Phillips3 and

Ian N M Day1

Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by

meltMADGE (Human Mutation 2006) (cat.P114)

MC4R A87D > (Appetite++) > BMI 31.5kg/m2

Does everybody have “one worst gene”?

Can we help them (cf phenylketonuria)?

Page 8: Ian Day Edited Presentation

From RV-CD to CV-CD

• Rare variant – common disease

• Common variant – common disease

Page 9: Ian Day Edited Presentation

BMI GWAS - SNPs near MC4R

Page 10: Ian Day Edited Presentation

BMI GWAS - SNPs near MC4R

Page 11: Ian Day Edited Presentation

Forest Plot / Meta-Analysis of Cohorts

MC4R lead SNP in replication studies

Common variants near MC4R are associated with fat mass, weight and risk of

obesity.Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, Beckmann JS, Berndt SI; Prostate, Lung, Colorectal, and Ovarian

(PLCO) Cancer Screening Trial, Jacobs KB, Chanock SJ, Hayes RB, Bergmann S, Bennett AJ, Bingham SA, Bochud M, Brown M, Cauchi S, Connell JM, Cooper C,

Smith GD, Day I, Dina C, De S, Dermitzakis ET, Doney AS, Elliott KS, Elliott P, Evans DM, Sadaf Farooqi I, Froguel P, Ghori J, Groves CJ, Gwilliam R, Hadley D, Hall

AS, Hattersley AT, Hebebrand J, Heid IM; KORA, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Herrera B, Hinney A, Hunt SE, Jarvelin MR, Johnson T, Jolley

JD, Karpe F, Keniry A, Khaw KT, Luben RN, Mangino M, Marchini J, McArdle WL, McGinnis R, Meyre D, Munroe PB, Morris AD, Ness AR, Neville MJ, Nica AC, Ong KK,

O'Rahilly S, Owen KR, Palmer CN, Papadakis K, Potter S, Pouta A, Qi L; Nurses' Health Study, Randall JC, Rayner NW, Ring SM, Sandhu MS, Scherag A, Sims MA,

Song K, Soranzo N, Speliotes EK; Diabetes Genetics Initiative, Syddall HE, Teichmann SA, Timpson NJ, Tobias JH, Uda M; SardiNIA Study, Vogel CI, Wallace C,

Waterworth DM, Weedon MN; Wellcome Trust Case Control Consortium, Willer CJ; FUSION, Wraight, Yuan X, Zeggini E, Hirschhorn JN, Strachan DP, Ouwehand WH,

Caulfield MJ, Samani NJ, Frayling TM, Vollenweider P, Waeber G, Mooser V, Deloukas P, McCarthy MI, Wareham NJ, Barroso I, Jacobs KB, Chanock SJ, Hayes RB,

Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Kraft P, Hankinson SE, Hunter DJ, Hu FB, Lyon HN, Voight BF, Ridderstrale M, Groop L, Scheet P, Sanna S,

Abecasis GR, Albai G, Nagaraja R, Schlessinger D, Jackson AU, Tuomilehto J, Collins FS, Boehnke M, Mohlke KL.

Nat Genet. 2008 Jun;40(6):768-75. Epub 2008 May 4.

Page 12: Ian Day Edited Presentation

Effect size of SNP locus near MC4R

Page 13: Ian Day Edited Presentation

Slide deleted

Page 14: Ian Day Edited Presentation

Slide deleted

Page 15: Ian Day Edited Presentation

Slide deleted

Page 16: Ian Day Edited Presentation

Helicopter view of genome+diseases:

cGWAS browser

Page 17: Ian Day Edited Presentation

What Sells to the Public?

• Judged by Internet traffic

• 1. Internet (indexing by web crawlers)

• 2. Sex

• 3. Genealogy

Page 18: Ian Day Edited Presentation

Slide deleted

Page 19: Ian Day Edited Presentation

Slide deleted

Page 20: Ian Day Edited Presentation

Slide deleted

Page 21: Ian Day Edited Presentation

Slide deleted

Page 22: Ian Day Edited Presentation

What Sells to the Doctors?• Genetic information that will help clinical process

• 1. diagnosis

• 2. prognosis

• 3. monitoring

• 4. screening

• 5. Non-directive counselling /reproductive choice

• 6. !! Not the patient’s right to know

Page 23: Ian Day Edited Presentation

Some real clinical examples

(single targetted gene tests)

• TPMT / thiopurines azathioprine, 6-mercaptopurine and 6-

thioguanine / organ Tx / autoimmune disease/ leukaemias

• Her2/NEU / breast cancer drug response

• VKORC1/CYP2C9 / warfarin dosing

• UGT1A1 /Gilbert’s / irinotecan / colon cancer

• DPYD, TS / 5-fluorouracil / gastric cancer

• (ABO) – blood group 1900-1925

Page 24: Ian Day Edited Presentation

Who gets the statins?

Average prescribing cutpoint

Red genotype over-represented and blue genotype under-represented relative

to black genotype. If we know the curves, then we could just use the genotype

ratios in those getting the statin, to determine the average prescribing cutpoint

Genotype ratio treatment index (GRTI)

NHS research of service delivery?

Page 25: Ian Day Edited Presentation

What does it all cost (2009)?

• 600,000 common polymorphisms (GWAS)

• £300 from 23andMe [NB £40 200K panels imminent]

• ‘Complete’ genome sequencing (NGS)

• £50,000

• 5 year goal of 1,000 dollar genome

• The cost of making sense of it all.

• The cost of leveraging value (to whoever) of that meaning

Page 26: Ian Day Edited Presentation

Urban(e) Dog Tags? (slide modified)• identity

• blood type and history of inoculations

• Blood group

• Statin myopathy risk

• CFTR delta508, HBB E6V

• ALDH2 status

• BCHE D70G

• LCT

• Norwalk virus resistance

• MC1R, OCA2

• What I would really like for Xmas is my complete genome sequence!

Page 27: Ian Day Edited Presentation